Data from The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias
Maria Vittoria Verga Falzacappa(University of Trieste), Pier Giuseppe Pelicci(Office of Technology Transfer), Andrea Ghelli Luserna di Rorà(Fondazione Pisa), Lüder Hinrich Meyer(Universität Ulm), Chiara Ronchini(European Institute of Oncology), Stefania Orecchioni(European Institute of Oncology), Ilaria Iacobucci(St. Jude Children's Research Hospital), Klaus‐Michael Debatin(German Centre for Cardiovascular Research), Francesco Bertolini(European Institute of Oncology), Giovanni Martinelli(University of Bologna), Mario Faretta(IFOM)
Cited by 0
Related Papers
Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018
|Cell Death and Differentiation|2018|6.6k
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
|Nature reviews. Cancer|2006|2.2k
Monoclonal Antibody-Mediated Tumor Regression by Induction of Apoptosis
|Science|1989|1.7k
Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)
|Nature|1995|1.6k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k